-
31.发明申请Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases 有权可溶性糖胺聚糖酶和制备和使用可溶性糖胺聚糖酶的方法公开(公告)号：US20110008309A1
公开(公告)日：2011-01-13
申请号：US12802864
申请日：2010-06-15
CPC分类号： A61K38/47 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C12N9/2408 , C12Y302/01035 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
摘要翻译： 本发明涉及新型可溶性中性活性透明质酸酶糖蛋白（sHASEGPs）的发现，其制备方法及其用于促进其它分子的施用或减轻糖胺聚糖相关病理学的用途。 描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。 包括改进的氨基末端前导肽，其增强sHASEGP的分泌。 本发明还包含重组sHASEGP的唾液酸化和聚乙二醇化形式，以增强天然存在的屠宰酶的稳定性和血清药代动力学。 进一步描述了衍生自真核细胞的基本上纯化的重组sHASEGP糖蛋白的合适制剂，其产生其最佳活性所需的适当糖基化。
-
32.发明申请公开(公告)号：US20100211015A1
公开(公告)日：2010-08-19
申请号：US12660869
申请日：2010-03-04
CPC分类号： A61K38/47 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C12N9/2408 , C12Y302/01035 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
-
公开(公告)号：US20090181013A1
公开(公告)日：2009-07-16
申请号：US12378969
申请日：2009-02-20
IPC分类号： A61K39/395 , A61K38/46 , A61K31/7088
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
-
公开(公告)号：US09677062B2
公开(公告)日：2017-06-13
申请号：US13374500
申请日：2011-12-28
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
-
公开(公告)号：US09677061B2
公开(公告)日：2017-06-13
申请号：US12928890
申请日：2010-12-21
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
-
公开(公告)号：US20140199282A1
公开(公告)日：2014-07-17
申请号：US13999454
申请日：2014-02-26
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
-
37.发明授权Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof 有权可溶性透明质酸酶糖蛋白（sHASEGP），其制备方法，用途及其组合物公开(公告)号：US08772246B2
公开(公告)日：2014-07-08
申请号：US13694005
申请日：2012-10-18
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
摘要翻译： 提供可溶性中性活性透明质酸酶糖蛋白（sHASEGP），其制备方法及其用于促进其它分子的给药或减轻糖胺聚糖相关病理学的用途。 描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。 包括改进的氨基末端前导肽，其增强sHASEGP的分泌。 还提供了sHASEGP的唾液酸化和聚乙二醇化形式。 还提供了通过施用sHASEGP的治疗方法及其修饰形式。
-
38.发明授权Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP) 有权通过施用可溶性透明质酸糖蛋白（sHASEGP）治疗水肿的方法公开(公告)号：US08765685B2
公开(公告)日：2014-07-01
申请号：US13506783
申请日：2012-05-16
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
摘要翻译： 提供可溶性中性活性透明质酸酶糖蛋白（sHASEGP），其制备方法及其用于促进其它分子的给药或减轻糖胺聚糖相关病理学的用途。 描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。 包括改进的氨基末端前导肽，其增强sHASEGP的分泌。 还提供了sHASEGP的唾液酸化和聚乙二醇化形式。 还提供了通过施用sHASEGP的治疗方法及其修饰形式。
-
39.发明授权公开(公告)号：US08580252B2
公开(公告)日：2013-11-12
申请号：US13507540
申请日：2012-07-06
CPC分类号： A61K38/47 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C12N9/2408 , C12Y302/01035 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
-
40.发明授权公开(公告)号：US08257699B2
公开(公告)日：2012-09-04
申请号：US13374248
申请日：2011-12-15
CPC分类号： A61K38/47 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , C12N9/2408 , C12Y302/01035 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.101 秒)
